alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
[Federal Register Volume 60, Number 88 (Monday, May 8, 1995)]
[Proposed Rules]
[Page 22542]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 95-11211]



=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF TRANSPORTATION

Federal Railroad Administration

49 CFR Part 214

[FRA Docket No. RSOR 13, Notice No. 4]
RIN 2130-AA86


Roadway Worker Protection

AGENCY: Federal Railroad Administration (FRA); DOT.

ACTION: Schedule of Additional Advisory Committee Meetings.

-----------------------------------------------------------------------

SUMMARY: The Federal Railroad Administration is announcing an 
additional meeting of the Advisory Committee on Regulatory negotiation 
(concerning the protection of railroad employees who work on or 
adjacent to track and face the risk of injury from moving trains and 
equipment).

DATES: The Advisory Committee (Committee) will hold an additional 
meeting on the following dates:

1. Tuesday, May 16, 1995.
2. Wednesday May 17, 1995.

ADDRESSES: The meeting will be held in the 6th floor Conference room at 
the headquarters of the Association of American Railroads (AAR). The 
AAR's headquarters is located at 500 F Street N.W., Washington, D.C. 
20001.

FOR FURTHER INFORMATION CONTACT: Cynthia B. Walters, Trial Attorney, 
Office of Chief Counsel, FRA 400 7th Street, SW, Room 8201, Washington, 
D.C. 20590 (Telephone: 202-366-0443).

SUPPLEMENTARY INFORMATION: On August 17, 1994 FRA published a notice of 
intent to establish an Advisory Committee (59 FR 42200). FRA also 
published a notice establishing this Committee on January 5, 1995 (60 
FR 1761), as well as publishing a notice of scheduled meetings on 
February 15, 1995 (60 FR 8619). Consistent with these notices, the 
continued objective of this Committee is to produce a report, including 
a draft notice of proposed rulemaking (NPRM) recommending a course of 
action for FRA to follow that will prevent roadway worker injuries and 
fatalities.
    The committee members, facilitators, and FRA determined that an 
additional meeting was needed to resolve pending issues. With this in 
mind, FRA continues to believe that public participation is critical to 
the success of this process. This negotiation session will also be open 
to the public, in accordance with the Federal Advisory Committe Act 
(Pub. L. 92-463).

    Issued this 2nd day of May, 1995.
S. Mark Lindsey,
Chief Counsel, Federal Railroad Administration.
[FR Doc. 95-11211 Filed 5-5-95; 8:45 am]
BILLING CODE 4910-06-P
Aaron L. COOPER, petitioner, v. Jeffrey BEARD, Secretary, California Department of Corrections and Rehabilitation.

No. 12-8806.

Supreme Court of the United States

April 15, 2013.

Petition for writ of certiorari to the United States Court of Appeals for the Ninth Circuit denied.
UNITED STATES DISTRICT COURT

NORTHERN DISTRICT OF INDIANA

SOUTH BEND DIVISION

KRISTI OBLINGER and WAYNE 

OBLINGER,

Plaintiffs,

v.

NEW ENGLAND COMPOUNDING 

PHARMACY, INC. d/b/a NEW 

ENGLAND COMPOUNDING CENTER, 

BARRY AND LISA CADDEN, and 

GREGORY CONIGLIARO,

Defendants.

)

)

)

)

)

)

)

)

)

)

)

)

)

)

CIVIL ACTION NO: 3:12-CV-820-RL-CAN

UNOPPOSED MOTION FOR EXTENSION OF TIME

TO RESPOND TO PLAINTIFFS’ COMPLAINT

Pursuant to L.R. 6.1., Defendants Barry and Lisa Cadden, and Greg Conigliaro 

(“Defendants”), by counsel, hereby move this Court for an extension of time to respond to 

Plaintiffs’ Complaint, up to and including April 19, 2013. Defendants’ Answer is currently due 

February 18, 2013. Plaintiffs’ counsel has been consulted and has no objection to the requested 

extension. 

WHEREFORE, Defendants, by counsel, pray for an Order allowing Defendants up to and 

including April 19, 2013 to respond to Plaintiffs’ Complaint, and for all other relief just and 

proper in the premises.

LEWIS WAGNER LLP

By: /s/ Kameelah Shaheed-Diallo

DINA M. COX, #18590-49

KAMEELAH SHAHEED-DIALLO, #28058-49

ROBERT M. BAKER IV, #25471-49

JANELLE M. KILIES, #30708-49

Attorneys for Defendants 

case 3:12-cv-00820-RL-CAN document 10 filed 02/14/13 page 1 of 2
2

CERTIFICATE OF SERVICE

This is to certify that a copy of the foregoing has been filed with the Clerk of the Court 

on February 14, 2013 using the CM/ECF system which sent notification of this filing to the 

following: 

Douglas D. Small

Edmond W. Foley

FOLEY & SMALL

1002 E Jefferson Blvd

South Bend IN 46617

Counsel for Plaintiffs 

/s/ Kameelah Shaheed-Diallo

KAMEELAH SHAHEED-DIALLO

LEWIS WAGNER, LLP

501 Indiana Avenue, Suite 200

Indianapolis, IN 46202

Phone: (317) 237-0500

FAX: (317) 630-2790

kshaheed-diallo@lewiswagner.com

Q:\NECC\25 - Oblinger\Federal Pleadings\MET.docx

case 3:12-cv-00820-RL-CAN document 10 filed 02/14/13 page 2 of 2
[Federal Register Volume 60, Number 86 (Thursday, May 4, 1995)]
[Notices]
[Page 22037]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 95-11041]



-----------------------------------------------------------------------


DEPARTMENT OF AGRICULTURE
Office of the Secretary


Agricultural Biotechnology Research Advisory Committee Meeting

    In accordance with the Federal Advisory Committee Act of October 
1972 (Pub. L. 92-463, 86 Stat. 770-776), the U.S. Department of 
Agriculture (USDA), Research, Education, and Economics, announces the 
following advisory committee meeting:

    Name: Agricultural Biotechnology Research Advisory Committee.
    Date: June 26, 1995.
    Time: 9:00 a.m. to approximately 5:00 p.m.
    Place: Club Room, Westpark Hotel, 1900 North Fort Myer Driver, 
Arlington (Rosslyn), Virginia 22209.
    Type of Meeting: This meeting is open to the public. Persons may 
participate in the meeting as time and space permit. Members of the 
public wishing to speak at the meeting may be given such an 
opportunity at the discretion of the Chair.
    Comments: The public may file written comments before or after 
the meeting with the contact person specified below.
    Purpose: To review matters pertaining to agricultural 
biotechnology research and to develop advice for the Secretary 
through the Under Secretary for Research, Education, and Economics 
with respect to policies, programs, operations and activities 
associated with the conduct of agricultural biotechnology research.
    The items to be considered at this meeting include performance 
standards for research with genetically modified aquatic organisms.
    Contact Persons: Dr. Alvin L. Young, Director, or Dr. Daniel D. 
Jones, Deputy Director, Office of Agricultural Biotechnology, 
Cooperative State Research, Education, and Extension Service, 
Department of Agriculture, Room 3868, South Building, 14th and 
Independence Avenue SW., Washington, D.C. 20250-0904, phone (202) 
720-5853.

    Done at Washington, D.C., this 17th day of April, 1995.
Floyd P. Horn,
Acting Under Secretary, Research, Education, and Economics.
[FR Doc. 95-11041 Filed 5-3-95; 8:45 am]
BILLING CODE 3410-22-M
Exhibit 31.2CERTIFICATION OF CHIEF FINANCIAL OFFICERI, Craig A. McCollam, certify that:1. I have reviewed this quarterly report on Form 10-Q of Dionex Corporation; 2. Based on my knowledge, this report does not contain any untrue statement of a material factor omit to state a material fact necessary to make the statements made, in light of thecircumstances under which such statements were made, not misleading with respect to the periodcovered by this report; 3. Based on my knowledge, the financial statements, and other financial information included inthis report, fairly present in all material respects the financial condition, results ofoperations and cash flows of the registrant as of, and for, the periods presented in thisreport; 4. The registrant’s other certifying officer(s) and I are responsible for establishing andmaintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and15d-15(e)) and internal control over financial reporting (as definedin Exchange Act Rules 13a-15(f) and15d-15(f) for the registrant and have: (a) Designed such disclosure controls and procedures, or caused such disclosure controls andprocedures to be designed under the Company’s supervision, to ensure that material informationrelating to the registrant, including its consolidated subsidiaries, is made known to us byothers within those entities, particularly during the period in which this report is beingprepared;  (b) Evaluated the effectiveness of the registrant’s disclosure controls and procedures andpresented in this report the Company’s conclusions about the effectiveness of the disclosure controlsand procedures, as of the end of the period covered by this report based on such evaluation;  (c) Disclosed in this report any change in the registrant’s internal control over financialreporting that occurred during the registrant’s most recent fiscal quarter (the registrant’sfourth fiscal quarter in the case of an annual report) that has materially affected, or isreasonably likely to materially affect, the registrant’s internal control over financialreporting; and5. The registrant’s other certifying officer(s) and I have disclosed, based on the Company’s most recentevaluation of internal control over financial reporting, to the registrant’s auditors and theaudit committee of registrant’s board of directors (or persons performing the equivalentfunctions): (a) All significant deficiencies and material weaknesses in the design or operation ofinternal control over financial reporting which are reasonably likely to adversely affectthe registrant’s ability to record, process, summarize and report financial information; and  (b) Any fraud, whether or not material, that involves management or other employees who havea significant role in the registrant’s internal control over financial reporting.   Date: May 10, 2006     /s/ Craig A. McCollam   Craig A. McCollam  Vice President and Chief Financial Officer
Paul L. SCHAFFER, petitioner, v. Kenneth R. CAMERON, Superintendent, State Correctional Institution at Cresson, et al.

No. 12-9049.

Supreme Court of the United States

April 29, 2013.

Petition for writ of certiorari to the United States Court of Appeals for the Third Circuit denied.
isis Qual «gli pga iy
384 ead) oN a YG) dl y
BNa¥) Alaa gg Warde (GE ai
Fah 43 Agdea) Quay anal
Oa gala Gaal

2
|

(agh AS gu gall / SUakall A364) "Stal! AL
B 4a 3 78 5 )oa daps sic GN 5 Ls Gael! eee
ACL 24 15 pe sey (Angia daa 25.5) Gulgia

— <= —
Saal co gall GUS 8 dad Cis 85 (gaudy Jf Ll qual Guia Balols all cag dS "Sth" OLDE od Ugendal cll gual) Gye ae atlas cof Club Lael Ul cu gh lS paul
Foe Cigte Ayabea yd 32 pay cplisl gla) baile (ple veil) 4848 Jala e.g JS Ul quali Gules a gli y
jae Gosnell Ge OSs -SlQuls
dl clue) (205 Bytes SUG Cul aL) ai nd -

gly Le ty yi Aaya (gb fad

cAagt Gal gal cgi Gaal) AMG Ayia CU Gf gD aucay
age ee

Aye) 68 taal duc o cole sisal aru y

Cel) cl) hee pl adil y

Gelie (pile plan JANI & puta ge slog of sldel uli y

Goal) 4nd! a yhl v

9810 Qa Lapua) ally

-4

1 > :

Udlus Aghia) nf Crud af Ly! gualall Co) Apaaaall Bay) Gall g
"UDI pf AGUS he uly Cyl gual ty yi ails ald . ya pally
aaa) Lgatans (598 Ae pita gall g Adpel) SUaeal) “Luu

lS JS cod Quill! dylan (8 adlus
Aagoual) Ay Jats A389) ay ct ol
Orlando CORONEL, Appellant, v. U.S. BANK, N.A., etc., Appellee.

No. 3D18-1653

District Court of Appeal of Florida, Third District.

Opinion filed June 19, 2019

**DECISION WITHOUT PUBLISHED OPINION**

Affirmed.
Letter Agreement



 Exhibit 10.1 
 January 27, 2009 
 Richard B. Brewer 
 President
and Chief Executive Officer 
 ARCA biopharma, Inc. 
 8001 Arista
Place, Suite 200 
 Broomfield, CO 80021 
  

	Re:	Executive Severance Benefit 

 Dear Mr. Brewer:

 Congratulations on the successful completion of the merger. As you are aware, consummation of the merger constitutes a “Change in Control” under
the terms of the Nuvelo, Inc. Executive Change in Control and Severance Benefit Plan, as amended August 1, 2007 (the “Plan”). In connection with the merger, I have resigned from my position as General Counsel and Secretary of Nuvelo,
Inc. (now known as ARCA biopharma, Inc., or the “Company”), but have agreed to remain as the Company’s Chief Financial Officer and Treasurer for a transitional period ending March 31, 2009 (the “Transition Period”),
during which time, I agree to assist with the preparation and filing of the Company’s annual report on Form 10-K for the fiscal year ended December 31, 2008 and to assist management with planning, finance, financial reporting and other
corporate governance matters (collectively, the “Duties”). Notwithstanding these Duties, my change in function constitutes a “Constructive Termination” pursuant to the terms of the Plan. As a result, I am now entitled to
“Change in Control Severance” benefits under the Plan, but agree (a) to defer the effective date of the “Constructive Termination” and my rights to receive severance benefits under the Plan until the expiration of the
Transition Period and (b) to perform the Duties summarized above during the Transition Period, in consideration of the Company’s agreeing as follows: 
 1. Upon satisfactory completion of the Duties, at the end of the Transition Period, the Company shall pay me in lump sum a retention bonus of $50,000 (net of applicable withholdings). 
 2. Concurrently with the payment of the retention bonus, the Company shall pay me in lump sum an amount equal to 50% of the aggregate “Base Severance Benefit”
and “Bonus Severance Benefit” that I am owed under the Plan (net of applicable withholdings). The Company shall pay me the balance of the “Base Severance Benefit” and “Bonus Severance Benefit” that I am owed under the
Plan by no later than September 30, 2009 (net of applicable withholdings). 
 3. The Company shall pay all other benefits (net of applicable
withholdings) to which I am owed under the Plan as if the effective date of the Constructive Termination is March 31, 2009. 







 Please acknowledge your agreement to the foregoing by countersigning in the space below. All the best. 
  

	
	Sincerely,
	
	/s/ Lee Bendekgey
	Lee Bendekgey



									
			
	Agreed to this 2nd day of February, 2009:	 		 	
			
	ARCA BIOPHARMA, INC.	 		 	
					
	By:	 	/s/ Christopher D. Ozeroff	 		 		 	
	Name: Christopher D. Ozeroff	 		 		 	
	Title: Executive Vice President Business	 		 		 	
	Development and General Counsel
[Federal Register Volume 60, Number 78 (Monday, April 24, 1995)]
[Notices]
[Page 20078]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 95-10115]



=======================================================================
-----------------------------------------------------------------------

COMMISSION ON IMMIGRATION REFORM

Consultation on Refugee and Humanitarian Admissions


Announcement of Commission Consultation

    This notice announces a consultation to be held by the U.S. 
Commission on Immigration Reform in Washington, D.C. on April 25, 1995. 
The Commission, created by Section 141 of the Immigration Act of 1990, 
is mandated to review the implementation and impact of U.S. immigration 
policy and report its findings to Congress. An interim report, U.S. 
Immigration Policy: Restoring Credibility, was issued on September 30, 
1994; the final report is due in 1997.
    The consultation participants will include the Commissioners, 
researchers, current and former Administration officials, Congressional 
staff, and representatives of international and non-governmental 
organizations. The consultation will examine U.S. refugee and 
humanitarian admissions policies.

    Date: April 25, 1995.
    Time: 9:00 am-2:15 pm.
    Address: Carnegie Endowment for International Peace, 2400 N Street, 
N.W., Washington, D.C. 20037-1153.
    For Further Information Contact: Paul Donnelly (202) 673-5348.

    Dated: April 19, 1995.
Susan Martin,
Executive Director.
[FR Doc. 95-10115 Filed 4-20-95; 10:40 am]
BILLING CODE 6820-97-M
#### Gustavo Daniel MATTIELLO, Petitioner, v. John ASHCROFT, Attorney General, Respondent.

No. 03-73542.

United States Court of Appeals, Ninth Circuit.

Submitted May 10, 2004.*

Decided May 17, 2004.

Michael S. Cabrera, Law Offices of Michael S. Cabrera, Huntington Park, CA, for Petitioner.

Regional Counsel, Western Region, Immigration & Naturalization Service, Laguna Niguel, CA, NVL — District Counsel, Office of the District Counsel, Department of Homeland Security, Las Vegas, NV, Ronald E. LeFevre, Chief Legal Officer, Office of the District Counsel, Department of Homeland Security, San Francisco, CA, Julia K. Doig, Esq., Song Park, Esq., DOJ — U.S. Department of Justice, Washington, DC, for Respondent.

Before: CANBY, KOZINSKI, and PAEZ, Circuit Judges.

*

 The panel unanimously finds this case suitable for decision without oral argument. *See*Fed. R.App. P. 34(a)(2).

MEMORANDUM **

Gustavo Daniel Mattiello, a native and citizen of Argentina, petitions for review of the Board of Immigration Appeals’ *551(“BIA”) decision summarily affirming an immigration judge’s denial of his application for asylum, withholding of removal and relief under Article 3 of the Convention Against Torture. We dismiss the petition for review for lack of jurisdiction.

We lack jurisdiction to consider Mattiello’s ineffective assistance of counsel claim, his sole contention on appeal, because Mattiello failed to raise it with the BIA. *See Ontiveros-Lopez v. INS,*213 F.3d 1121, 1124 (9th Cir.2000) (‘We ... require an alien who argues ineffective assistance of counsel to exhaust his administrative remedies by first presenting the issue to the BIA”).

PETITION FOR REVIEW DISMISSED.

**

 This disposition is not appropriate for publication and may not be cited to or by the courts of this circuit except as may be provided by 9th Cir. R. 36-3.
UNITED STATES DISTRICT COURT 

NORTHERN DISTRICT OF CALIFORNIA

CIVIL MINUTES 

Date: 3/16/17 Time: 22 minutes Judge: WILLIAM ALSUP 

Case No.: 3:17-cv-00939-WHA Case Name: Waymo LLC v. Uber Technologies, Inc. et al., 

Deputy Clerk: Dawn Logan Court Reporter: Belle Ball 

Attorney for Plaintiff: Charles Verhoven; David Perlson; Jordan Jaffe; Melissa Baily 

Attorney for Defendants: Arturo Gonzalez; Michael Jacobs

 

PROCEEDINGS 

CMC - HELD 

PRETRIAL SCHEDULE: 

See separate orders. 

Case 3:17-cv-00939-WHA Document 62 Filed 03/16/17 Page 1 of 1
ᎢᏳᏍᏗ 2 ᎧᎳᏎᏥ ᏂᏱᎦᎵᏍᏗᏍᎬ ᎾᎯᏳ ᎯᏰᎸ ᎥᏝ ᏂᎪᏢᏍᎬᎾ ᎠᎴᏃ ᎢᏑᎳᏂ ᏂᎬᏗᏍᎬᎾ ᎣᏍᏓ. ᎾᏍᎩ ᏄᏍᏛ ᏓᏂᏩᏛᎡᎲ ᎤᏠᏱᎭ ᎾᏍᎩ ᏧᎾᏔᎾ. ᎢᎦᏓ ᏂᏕᎦᎵᏗᏍᎬ ᎾᏍᎩᎾᎢ ᎦᎸᎳᏗᎨᏍᏗ ᎦᎾᏰᎩ ᏂᏣᎵᏍᏓᏁᎰᎢ ᎾᏍᎩᎾ ᎢᏳᏍᏗ 2 ᎧᎳᏎᏥ ᎤᏠᏯᏍᏗ:

ᎦᎪᏃ ᏄᏍᏛ ᎠᎶᎳᏙᏗᏍᎩ ᎿᎢ ᎧᎳᏎᏥ?

ᎾᏍᎩ 1 ᎾᏃ 10 ᎤᎶᏒᏍᏔᏅ  ᏧᎾᏔᎾ ᎾᎿᎢ ᎤᎾᏓᏚᏕᏫᏛ ᏗᎦᏚᎿᎢ ᎨᏒᎢ ᎠᏁᎲ ᎾᏍᎩ ᎢᏳᏍᏗ 1 ᎠᎴᏃ ᎢᏳᏍᏗ2 ᎧᎳᏎᏥ. ᎢᏳᎾᏍᏗ ᏴᏫ ᎠᎴ ᏴᏫ ᎠᏰᎵ ᎠᏁᎲᎢ ᎠᏂᎦᏲᎵᎨᏍᏗ ᎠᎴ ᏄᎾᏓᎴ ᏧᎾᏓᎴᏅᏓ ᏚᎾᏓᏡᎬᎢ ᏚᏁᎲᎩ ᎾᏍᎩ ᎦᎸᎳᏗᏉ ᎠᏍᏓᏯ ᏄᎵᏍᏓᏁᎲᎢ ᎾᏍᎩ ᎧᎳᏎᏥ ᎠᎴ ᎧᎳᏎᏥ-ᏧᏠᏱ ᎢᏧᏍᏗ ᏧᏦᏎᏍᏗ ᎨᏒᎩ. ᎾᏍᎩᎾ  ᏱᏓᏟᎶᏍᏔᎾ, ᎠᎹᏰᏟ ᎡᎯ ᎠᏴᏫᏯ/ᎠᎴᏍᎧ ᏅᏁᎯᏯ ᏧᎾᏔᎾ ᎨᏒᎢ ᎾᎢ ᏓᎨᏥᏩᏛᎡᎵ ᎾᏍᎩ ᎢᏳᏍᏗ 2 ᎧᎳᏎᏥ ᎾᎢ ᏦᎢ ᎾᎥᏂᎨᏍᏗ ᏄᏓᎷᎸᎾ ᎢᏳᏩᎫᏗ ᎾᏍᎩ ᎤᏟ ᎢᎦᎢ ᎨᏎᏍᏗ ᏏᏃ ᎥᏝ-ᎠᏍᏆᏂ ᏴᏫᏁᎦ ᏧᎾᏔᎾ.

ᎧᎳᏎᏥ ᏗᎦᎾᏗᏅᏗ ᎤᏚᏓᎴᏒ ᎠᎴᏃ ᎤᏃᎯᏳᏔᏅᎢ ᎬᏗ ᎾᏍᎩ FDA

ᎠᏂᏴᏫ ᎠᏁᎲ ᎾᏍᎩ ᎢᏳᏍᏗ 1 ᎠᎴᏃ ᎢᏳᏍᏗ 2 ᎧᎳᏎᏥ ᎬᏙᏗ ᏡᎪᏏ ᏗᏎᎯᎯ ᎠᎴ ᎠᎪᎵᏰᏍᎩ ᏧᎶᎵᎩ ᎾᎢ ᎠᎪᎵᏰᏍᎩ ᏄᏅᏅᎢ ᎩᎦ ᎧᎵᏤᏥ ᏂᏚᎩᏨᏂᏒ ᎢᎦ. ᎾᏍᎩ ᏂᏚᎵᏍᏔᏅ ᏥᏕᎵᏍᎩ ᏗᏧᎪᏙᏗ ᏧᎩᏨᏅᏓ ᏗᎦᏁᏟᏴᏍᏓ ᎾᏍᎩ  ᎠᏓᏅᏬᏗ, ᏣᏅᏖᏍᏗ ᎢᏳᏃ ᎦᎸᎳᏗ ᎠᎴᏃ ᎡᎳᏗ ᏓᏟᎶᎲᎢ ᎾᏍᎩ ᏡᎪᏏ ᏱᏂᏣᎵᏍᏓᏁᎭ, ᎠᎴ ᎰᎵᎨᏍᏓ ᏰᎵᎢ ᏣᏤᎵ ᎠᎵᏍᏓᏴᏗ ᎠᎴ ᏗᎫᎪᏙᏗ ᎦᏁᏟᏴᏍᏗ ᏣᏤᎵ ᏡᎪᏏ ᏓᏟᎶᎲᎢ.

ᎠᏂᏴᏫ ᎠᏁᎲ ᎾᏍᎩ ᎢᏳᏍᏗ 1 ᎧᎳᏎᏥ ᎤᏚᎸᏛ ᎤᏅᏌᏉ ᎢᏑᎳᏂ ᏧᎾᏓᏣᏲᏍᏗᎢ ᏂᏚᎩᏨᏂᏒ ᎢᎦ ᎾᎢ ᎲᏃᏓ ᏱᏣᎵᏍᏙᏗ ᎠᎴ ᏅᏩᏙᎯᏯᏛ. ᎾᏍᎩᏛ ᏰᎵᏊ ᎾᏍᏉ ᎤᏂᎩᏍᏗ ᎤᏍᏗ, ᎢᎦᏗᎭ ᏗᏓᏣᏲᏍᏗ ᎾᏍᎩ ᎢᏑᎳᏂ ᏂᎦᏅᎯᏒ ᎢᎦ ᎬᏗᏍᎬ ᎾᏍᎩ ᎢᏑᎳᏂ ᎦᏌᏙᏯᏍᎩ ᎠᎴᏃ ᎾᏍᎩ ᎤᏩᏌ ᏱᎬᏁᎯ ᎢᏑᎳᏂ ᎢᎦᎢ ᎠᏥᏣᏲᏍᏗ.   ᎤᎪᏗᏗ ᎠᏂᏴᏫ ᎾᏍᎩ ᎢᏳᏍᏗ 2 ᎧᎳᏎᏥ ᏰᎵᏉ ᎤᏚᎸᏛ ᎧᎳᏎᏥ ᏅᏬᏘᏃ ᎤᏄᏙᏓ. ᎯᎠᏃ ᏰᎵᏉ ᎠᏠᏯᏍᏓ ᏗᎩᏍᏓ, ᎢᏑᎳᏂ, ᎠᎴᏃ ᏅᏩᏓᎴ ᏗᏓᏣᏲᏍᏙᏗ ᏅᏬᏘᏃ

ᎧᎳᏎᏥ ᎠᎴ ᏅᎠᏯᏍᏗ ᎠᏂᏴᏫ ᏕᎨᏥᎪᎵᏰᏍᎬᎢ  

ᎾᏍᎩᏃ FDA ᏕᎦᏂᎳᏕᎲᎩ ᏧᏓᎴᏅᏓ ᎠᎾᏁᎳᏗᏙᎯ ᎾᎿᎢ ᎤᎠᏯᏍᏗ ᎠᏂᏴᏫ ᏕᎨᏥᎪᎵᏰᏍᎬᎢ. ᎢᏳᏃ ᏂᎯ ᏱᏁᎵᎭ Ꮎ ᎤᎠᏯᏍᏗ ᎠᏂᏴᏫ ᏕᎨᏥᎪᎵᏰᏍᎬᎢ ᏰᎵᏉ ᏚᏳᎪᏛ ᎨᏎᏍᏗ ᎾᏍᎩᎾ ᏂᎯ, ᎨᎯᎵᏃᎮᏓ ᏗᏣᏤᎵ ᏅᏩᏙᎯᏯᏛ ᎠᎾᏓᎦᏎᏍᏗᏍᎩ ᎠᏓᏁᏢᏍᎩ. ᏂᎯ ᏰᎵᏊ ᎾᏍᏉ  ᎠᏱᏍᏗ ᎾᏍᎩᎾ ᎤᎠᏯᏍᏗ ᎠᏂᏴᏫ ᏕᎨᏥᎪᎵᏰᏍᎬᎢ ᎾᎿᎢ ᏣᏤᎵ ᎢᎬᎾᏕᎾ ᎾᎿᎢ  www.clinicaltrials.gov.

ᎾᏍᎩᎾ ᎤᏟ ᎢᎦᎢ ᎧᏃᎮᏢᎥᏍᎩ ᎤᎾᎢ ᏅᏩᏙᎯᏯᏛ ᎢᎦᏘᎭᎢ, ᎠᏩᏛᎯᏓᏍᏗwww.fda.gov/healthequity.

ᎤᏙᎯᏳ ᎪᏪᎶᏗᎧᎳᏎᏥ ᎾᏍᎩ ᎥᏳᎩ ᏂᏕᎦᎵᏍᏗᏍᎬ ᎾᎯᏳ ᎩᎦ ᎧᎵᏤᏥ ᎠᏟᎶᎲᎢ ᎦᎸᎳᏗᏉ ᏱᏂᏣᎵᏍᏓᏁᎳ. ᎾᏍᎩ ᎠᏎᎸᎯ 30 ᎢᏳᏆᏗᏅᏓ ᎠᏂᏴᏫ ᎧᎳᏎᏥ ᎢᏳᎵᏍᏓᏁᎯ ᎠᏁᎲ ᎾᎿᎢ ᎤᎾᏓᏚᏕᏫᏛ ᏗᎦᏚᎿᎢ. ᎢᏴᏛ 1 ᎾᏃ 4 ᎠᏂᏴᏫ ᎠᏁᎲ ᎧᎳᏎᏥ ᎢᏳᎾᎵᏍᏓᏁᎯ ᎥᏝ ᏳᎾᏅᏔ ᎤᏁᎲᎢ. ᎧᎳᏎᏥ ᏰᎵᏃ ᎢᎦᏘᎭ ᏂᎨᏒᎾᏃ ᏱᏗᎬᏂᎯᏍᎩ ᎢᏳᎾᏍᏗ ᏴᏫ ᎠᎴ ᏴᏫ ᎠᏰᎵ ᎠᏁᎲᎢ ᎠᏂᎦᏲᎵᎨᏍᏗ ᎠᎴ ᏄᎾᏓᎴ ᏧᎾᏓᎴᏅᏓ ᏚᎾᏓᏡᎬᎢ. 

ᎣᏏ ᎾᎿᎢ ᎠᏂᎦᏲᎵᎨᎢ ᏅᏩᏙᎯᏯᏛ ᎠᎴ ᏅᏩᏙᎯᏯᏛ ᎢᎦᏘᎭᎢ  

ᎧᎳᏎᏥ

ᎦᏙᎤᏍᏗ ᎧᎳᏎᏥ?ᎧᎳᏎᏥ ᎾᏍᎩ ᎥᏳᎩ ᎾᏍᎩ ᏂᏕᎦᎵᏍᏗᏍᎬ ᎾᎯᏳ ᏡᎪᏏ ᎠᏟᎶᎲᎢ ᎾᎿᎢ ᎩᎦ ᏣᏁᎲᎩ (ᎩᎦ ᎧᎵᏤᏥ) ᎦᎸᎳᏗᏉ ᏱᏂᎦᎵᏍᏗᎭ. ᎢᏑᎳᏂ ᎾᏍᎩ ᎩᎬᎡᏙᎯ ᎤᏇᏓᏢᎢ ᎪᏢᏍᎩ ᏄᏩᏅ ᎤᏪᎳ ᏩᏂᎨᎢ ᎾᏍᎩᎾᎢ ᎠᏍᏕᎵᏍᎩ ᎦᏅᎪᏫᏍᏒ ᎧᎵᏤᏥ ᎤᎦᎾᏍᏓ ᎩᎦ ᏣᏁᎲᎩ ᎠᎴ ᎠᏴᎯᎲ ᏂᏕᏨᏅ ᏗᏙᏢᏍᎩ ᎾᏍᎩᎾ ᎠᏓᎵᏂᎪᎯᏍᏗᏍᎩ. ᎢᏳᏃ ᏂᎯ ᎧᎳᏎᏥ ᏱᎦᎵᏍᏓᏁᎢ ᏱᎩ, ᏞᏍᏗ ᏣᏰᎸᎯ ᏱᎪᏢᏍᎦ ᎠᎴᏃ ᎢᏑᎳᏂ ᏱᎬᏗ ᎣᏍᏓ.ᎠᏓᏎᎮᎯ ᏂᏚᎾᎵᏍᏓᏁᎲᎢ ᎥᎿᎢ ᎧᎳᏎᏥ ᎠᏠᏯᏍᏓ:

ᎾᏍᎩᏃ ᏔᎵ ᏄᎬᏫᏳᏒ ᎢᏧᏍᏗ ᎧᎳᏎᏥ: ᎢᏳᏍᏗ 1 ᎠᎴ ᎢᏳᏍᏗ 2.

ᎢᏳᏍᏗ 1 ᎧᎳᏎᏥ ᏂᏕᎦᎵᏍᏗᏍᎬ ᎾᎯᏳ ᎯᏰᎸ ᎥᏝ ᏂᎪᏢᏍᎬᎾ ᎢᏒᎳᏂ ᏅᏗᎦᎵᏍᏙᏗᎭ ᏣᏤᎵ ᎥᏳᎩ ᎬᏩᏠᎯᏍᏗ ᏂᎨᏒᎾ ᏗᏓᎦᏘᎴᎩ ᎠᎴ ᏓᏲᏍᏗᏍᎬ ᎾᏍᎩ ᏗᏙᏢᏍᎩ ᎾᏍᎩᎾᎢ ᎪᏢᏍᎩ ᎢᏒᎳᏂ. ᎠᏎᏍᎩᏂ ᏰᎵᏊ ᎢᏱᎦᎾᏄᎪᎢ ᎢᏴ ᎢᏳᏕᏘᏴᏓ ᎨᏒᎢ, ᎢᏳᏍᏗ 1 ᎧᎳᏎᏥ ᏄᏍᏛ ᏓᏂᏩᏛᎡᎲ ᎤᏠᏱᎭ ᎾᏍᎩ ᏗᏂᏲᏟ ᎠᎴ ᎩᎳ ᏧᎾᏔᎾ.  ᏂᎯ ᎾᎿ ᎦᎸᎳᏗᎨᏍᏗ ᎦᎾᏰᎩ ᎾᏍᎩᎾ ᎢᏳᏍᏗ 1 ᎧᎳᏎᏥ ᎢᏳᏃ ᏗᏣᎦᏴᎵᎨ, ᏗᏣᏓᏅᏟ, ᎠᎴᏃ  ᎨᏣᏙᎢ ᏳᏁᎭ ᎢᏳᏍᏗ 1 ᎧᎳᏎᏥ.

ᎾᏍᎩᏃ FDA, ᎾᏍᎩ ᏗᎦᏘᏲᎢ ᎭᏫᏂᏗᏢ ᎾᏍᎩ U.S. ᏗᎦᎸᏫᏍᏓᏁᏗ ᎥᎿᎢ ᏅᏩᏙᎯᏯᏛ ᎠᎴ ᏴᏫ ᎢᏗᏓᏛᏁᏗᎢ, ᏗᎵᏍᏕᎸᏙᏗ ᎾᏍᎩ ᎠᏰᎵ ᏅᏩᏙᎯᏯᏛ ᏄᎶᎾ ᎠᏚᏯᏍᏗᏍᎬᎢ ᎾᏍᎩ ᏄᎾᏰᎯᏍᏛᎾ ᎢᏳᎵᏙᏗ ᎨᏒᎢ, ᎠᎴ ᎤᎦᏎᏍᏗ ᎥᎿᎢ ᏴᏫ ᎠᎴ ᎦᎾᏜᎢ ᏗᎩᏍᏗ ᏧᏴᏍᏗ, ᎥᏳᎩ ᎠᎭᎷᎩᏍᎩ ᎠᎴ ᏐᎢ ᎬᏃᏓ ᏄᏍᏗᏓᏅ ᎠᎨᏎᏍᏔᏅᎩ ᏗᎦᎾᏗᏅᏗ ᎾᏍᎩᎾ ᎬᏫ ᎤᏅᏙᏗ, ᎠᎴ ᏅᏬᏘᏯᎢ ᏥᏂᏕᎬᎾᏗᏓᎾ. ᎾᏍᎩᏃ ᏗᎦᏘᏲᎢ ᎾᏍᏊ ᏄᏍᏛ ᏣᏚᏓᎴᏍᏗ ᎾᏍᎩᎾ ᏄᎾᏰᎯᏍᏛᎾ ᎠᎴ ᎤᎦᏎᏍᏗ ᎥᎿᎢ ᏃᎬᏅ ᎠᏰᎵ ᏄᏩᎿᏅ ᎠᎵᏍᏓᏴᏗ ᎬᏔᏂᏓᏍᏗ ᎠᏍᏆᏂᎪᏛᎢ, ᏗᏓᏅᎵᏰᏗ, ᎠᎵᏍᏓᏴᏗ ᏗᏑᏯᎾᎢ ᏧᎾᎵᏍᏕᎸᏙᏗ, ᎠᎴ ᏗᎦᎾᏗᏅᏗ ᎾᏍᎩᎾᎢ ᎠᏔᏃᎴᎪᎢ ᎠᎾᎦᎵᏍᎩ ᎤᏍᎦᏎᏗ ᎠᏔᏃᎴᎩ, ᎠᎴ ᎾᏍᎩᎾ ᏓᎳᏏᏗᏍᎬᎢ ᏦᎳ ᎠᎦᎾᏗᏅᏗ.

•       ᎤᏁᏉᏨᎯ ᎤᏔᏕᎩᏍᎬ ᎠᎴ ᎠᏗᎧᎵᏙᎲᎢ 

•     ᎤᏁᏉᏨᎯ ᎤᏲᏏᏍᎬᎢ

•     ᏚᏯᏪᎬᎢ

•     ᎤᏍᎪᎸᎢ ᎠᎪᏩᏘᏍᎬᎢ 

•     ᏚᏍᏓᎸ ᎾᏍᎩᎾᎢ ᎥᏝ ᏂᏚᏗᏍᎬᎾ 

•     ᏃᏛᎾ ᏄᏰᎵᏛ ᏄᏓᎨᏒ ᎤᏲᎱᏎᎲᎢ 

•     ᎤᎶᏒ ᏂᏚᏍᏛ ᎠᎴᏃ  ᏧᏣᏲᏍᏗ ᎾᎿᎢ ᏧᎳᏏᏕᎾ ᎠᎴᏃ ᏧᏬᏰᏂ

•  ᏰᎵᏉ ᎤᎶᏒᏍᏔᏅ ᎤᏓᎨᏗᏳ ᎨᏒᎢ ᎠᎴᏃ  ᎤᎶᏒᏍᏔᏅ ᎦᎵᏙᎯᏗ •  ᏰᎵᏉ 45 ᎢᏳᏕᏔᏴᏛ ᎠᎴᏃ ᎠᎦᏴᎳᎯᎨᏍᏓ •  ᏰᎵᏉ Ꮭ ᎤᏓᎵᏂᎩᏓ ᏱᎩ ᎤᎵᏖᎸᏂᏓᏍᏗᎢ •  ᏏᏓᏁᎸᎯ ᏧᎶᏒ ᎤᏁᎯ ᎨᏒᎢ ᎧᎳᏎᏥ  •  ᎢᎸᎯᏳ ᏤᎯ ᏄᎵᏍᏔᏅ ᎦᏁᎵᏛ ᎧᎳᏎᏥ
July 24, 1997

Via Facsimile

Ms. Ilona Adams                         Mr. James Mendelson
The Balcor Company                      The Balcor Company
2355 Waukegan Road, Suite A-200         2355 Waukegan Road, Suite A-200
Bannockburn, IL  60015                  Bannockburn, IL  60015
(847) 317-4462                          (847) 317-4462

Mr. Michael Bench                       Steven Levy, Esq.
Near North National Title Corporation   Katten Muchin & Zavis
222 N. LaSalle Street                   525 W. Monroe Street, Suite 1600
Chicago, IL  60601                      Chicago, IL  60661-3693
(312) 419-0569                          (312) 902-1061

     Re:  Sale and Escrow Agreement Among Vestar Development Co., Glendale
          Fashion Center Limited Partnership and Near North National Title 
          Company Escrow No. N942501A

Pursuant to paragraph 30 of the Sale Agreement as set forth in paragraph 1 of
the Ninth Amendment, Purchaser hereby provides written notice of its election
to exercise the option to extend the closing date for a 30-day period (its
fifth extension) through and including August 28, 1997.  Per my discussion with
Steve Levy, the $100,000 extension payment will be wired to Near North National
Title Company on Friday, July 25, 1997.  This shall also serve as Near North's
authorization to deposit such $100,000 in the same investment as the existing
escrow funds with the same maturation date as the existing investments as I
instructed on Wednesday, July 23.

If anyone has any questions concerning this, please contact me.

Sincerely,

/s/ Allan J. Kasen
----------------------------
Allan J. Kasen

AJK/ss

cc:  Alan G. Lieberman, via facsimile (847) 317-4462
     Jay B. Newman, via facsimile (213) 955-7999
     Edward Krasnove, via facsimile (310) 792-4620
     Lee T. Hanley
     Richard J. Kuhle
<PAGE>